ODC1 and myeloid sarcoma: Additionally, the ODC1 inhibitor can effectively enhance the chemotherapy sensitivity of PTCs (Fig. 7 and Supplementary Fig. 10), highlighting its potential clinical application in MS-related progressive or resistant EC.